2.835USD+2.72%Mkt Cap: 164.73M USDP/E: 10.54Last update: 2026-05-26
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap164.73M USD
Enterprise Value102.10M USD
Revenue (TTM)61.19M USD
Gross Profit22.72M USD
Net Income (TTM)8.57M USD
Revenue/Share1.083 USD
Last Price2.835 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees25
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS84833T1034
Valuation
P/E (Trailing)10.54
P/E (Forward)-2.42
PEG—
EV/EBITDA—
EV/Revenue1.67
P/S2.55
P/B2.57
EPS (TTM)0.27
EPS (Forward)-1.11
52W Range
0.656085% of range3.220
52W High3.220 USD
52W Low0.6560 USD
Profitability
Gross Margin37.13%
Oper. Margin-2921.70%
EBITDA Margin0.00%
Profit Margin14.38%
ROE14.52%
ROA12.44%
Growth
Revenue Growth-95.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.62M USD
CapEx (TTM)—
FCF Margin22.38%
FCF Yield8.31%
Net Debt-53.66M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.05
Current Ratio10.50
Quick Ratio10.23
Book Value/Sh1.046 USD
Cash/Share0.9690 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)4.000 USD
Target Range4.000 USD – 4.000 USD
# Analysts1
Ownership
Shares Out.57.90M
Float47.34M
Insiders22.52%
Institutions16.11%
Short Interest
Short Ratio2.6d
Short % Float2.46%
Short % Out.2.04%
Shares Short1.18M
Short (prev mo.)605.31K
Technical
SMA 502.580 (+9.9%)
SMA 2002.329 (+21.7%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)552.32K
Avg Vol (10d)635.40K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—